(59) testified tremelimumab (cytotoxic T lymphocyte–associated antigen 4 inhibitor) plus durvalumab (anti–PD-L1) or durvalumab monotherapy versus sorafenib in patients with unresectable HCC, which indicated significant improvement in overall survival after tremelimumab plus durvalumab compared to sorafenib and non-inferiority of durvalumab monotherapy was identified compared to sorafenib. Here, CD274 is linked to hepatocellular carcinoma.